Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript:
以下是Evogene Ltd.(EVGN)2024年第三季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Evogene reported Q3 2024 revenues of approximately $1.8 million, a decrease from Q3 2023's $3.8 million, primarily due to a decrease in licensing revenue from Lavie Bio.
The company recorded an operating loss of approximately $17.6 million in the first nine months of 2024, slightly improved from $18.9 million in the same period of 2023.
Financing expenses for the first nine months of 2024 were approximately $0.38 million, a shift from a financing income of $2.3 million in the first nine months of 2023.
Projected cash usage for 2024 is approximately $8 million to $10 million, a decrease from $12.5 million in 2023, following a reduction in workforce by 16% and other expense management strategies.
Evogene报告称,2024年第三季度收入约为180万美元,低于2023年第三季度的380万美元,这主要是由于Lavie Bio的许可收入减少。
该公司在2024年前九个月录得约1760万美元的营业亏损,较2023年同期的1,890万美元略有改善。
2024年前九个月的融资支出约为38万美元,与2023年前九个月的230万美元融资收入有所不同。
在员工裁员16%和其他费用管理策略之后,2024年的预计现金使用量约为800万至1000万美元,较2023年的1,250万美元有所减少。
Business Progress:
业务进展:
Evogene highlighted significant progress in seed production infrastructure notably in Kenya and Brazil for its subsidiary Casterra, which will support existing and future seed demands.
Lavie Bio announced the expansion of its bio-inoculant product, Yalos, to winter wheat and soybeans, and advancement of its bio-fungicide LAV321.
The company announced a collaboration with Google Cloud to develop a generative AI model for novel small molecule design, leveraging Evogene's AI tech engines.
Evogene强调了其子公司Casterra在种子生产基础设施方面的重大进展,特别是在肯尼亚和巴西,这将支持现有和未来的种子需求。
Lavie Bio宣布将其生物接种剂产品Yalos扩展到冬小麦和大豆,并推进其生物杀菌剂 LAV321。
该公司宣布与谷歌云合作,利用Evogene的人工智能技术引擎,为新的小分子设计开发生成式人工智能模型。
Opportunities:
机会:
Continued revenue growth anticipated for 2024, driven by existing seed orders from Casterra and new product launches from Lavie Bio.
Expansion into bioinformatics through collaboration with Google Cloud, positioning its AI tech engines at the forefront of novel molecule design.
受Casterra现有种子订单和Lavie Bio新产品推出的推动,预计2024年的收入将持续增长。
通过与谷歌云的合作扩展到生物信息学,将其人工智能技术引擎置于新分子设计的最前沿。
Risks:
风险:
Fluctuations in operating expenses and increased financial expenses related to warrants issued during fundraising could impact financial stability.
运营费用的波动以及与筹款期间发行的认股权证相关的财务支出增加可能会影响财务稳定。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。